- Reads 1
- Votes 0
- Parts 1
- Time <5 mins
Ongoing, First published Jun 03, 2023
Lorlatinib 100 mg (Lorbrexen) is a highly effective targeted therapy for patients with ALK-positive non-small cell lung cancer. Learn more about this medication, including its benefits, side effects, and dosage. Non-small cell lung cancer (NSCLC) is the most common type, accounting for 85% of all cases. Among patients with NSCLC, those diagnosed with ALK-positive tumors have a specific mutation in the anaplastic lymphoma kinase (ALK) gene. Lorlatinib, a medication designed to inhibit cancer cell growth and spread, can target this mutation. In this article, we will explore the benefits, side effects, and dosage of Lorlatinib 100 mg, effective treatment for ALK-positive NSCLC. Benefits of Lorlatinib 100 mg (Lorbrexen): Highly effective in treating ALK-positive NSCLC Can help shrink tumors and slow disease progression May provide a longer period of disease control than other treatments You can take this medication at home by mouth. Side Effects of Lorlatinib 100 mg (Lorbrexen): Nausea, vomiting, and diarrhea Fatigue and weakness Elevated liver enzymes Difficulty breathing and coughing Weight gain and edema Dosage and Administration of Lorlatinib 100 mg: Typically taken once daily with or without food The dose may adjust based on individual response and tolerance. Swallow tablets whole, do not crush or chew Store at room temperature away from moisture and heatAll Rights Reserved
Table of contents
Sign up to add Lorlatinib 100 mg (Lorbrexen) to your library and receive updates
or
You may also like
